Xencor, Inc.
(NASDAQ : XNCR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-3.80%191.441.2%$534.16m
TSROTESARO, Inc.
0.23%73.9514.4%$516.06m
CELGCelgene Corporation
-3.74%70.081.2%$510.98m
GILDGilead Sciences, Inc.
-2.91%68.150.9%$491.90m
ILMNIllumina, Inc.
-3.86%321.413.5%$363.96m
BIIBBiogen Inc.
-3.05%316.731.3%$352.14m
REGNRegeneron Pharmaceuticals, Inc.
-2.32%372.832.6%$248.08m
VRTXVertex Pharmaceuticals Incorporated
-4.12%172.211.9%$245.33m
AAgilent Technologies, Inc.
-2.34%70.231.5%$233.08m
ALXNAlexion Pharmaceuticals, Inc.
-4.49%115.602.0%$139.06m
SRPTSarepta Therapeutics, Inc.
-3.35%121.3815.4%$129.29m
NKTRNektar Therapeutics
-2.76%36.995.5%$106.49m
EXASExact Sciences Corporation
-4.30%71.7025.3%$105.84m
INCYIncyte Corporation
-0.91%64.512.5%$103.69m
LGNDLigand Pharmaceuticals Incorporated
-5.19%145.6123.1%$85.50m

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.